Cargando…
Biomarkers of evasive resistance predict disease progression in cancer patients treated with antiangiogenic therapies
Numerous antiangiogenic agents are approved for the treatment of oncological diseases. However, almost all patients develop evasive resistance mechanisms against antiangiogenic therapies. Currently no predictive biomarker for therapy resistance or response has been established. Therefore, the aim of...
Autores principales: | Pircher, Andreas, Jöhrer, Karin, Kocher, Florian, Steiner, Normann, Graziadei, Ivo, Heidegger, Isabel, Pichler, Renate, Leonhartsberger, Nicolai, Kremser, Christian, Kern, Johann, Untergasser, Gerold, Gunsilius, Eberhard, Hilbe, Wolfgang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4991441/ https://www.ncbi.nlm.nih.gov/pubmed/26956051 http://dx.doi.org/10.18632/oncotarget.7915 |
Ejemplares similares
-
Expression and release of glucose-regulated protein-78 (GRP78) in multiple myeloma
por: Steiner, Normann, et al.
Publicado: (2017) -
High levels of FLT3-ligand in bone marrow and peripheral blood of patients with advanced multiple myeloma
por: Steiner, Normann, et al.
Publicado: (2017) -
Spliced XBP1 Levels Determine Sensitivity of Multiple Myeloma Cells to Proteasome Inhibitor Bortezomib Independent of the Unfolded Protein Response Mediator GRP78
por: Borjan, Bojana, et al.
Publicado: (2020) -
Marine compounds inhibit growth of multiple myeloma in vitro and in vivo
por: Steiner, Normann, et al.
Publicado: (2015) -
The FMS like Tyrosine Kinase 3 (FLT3) Is Overexpressed in a Subgroup of Multiple Myeloma Patients with Inferior Prognosis
por: Steiner, Normann, et al.
Publicado: (2020)